Groupement Hospitalier Public du Sud de l'Oise - site de Senlis
- Address
- Avenue Paul Rougé, 60300 SENLIS, France
Groupement Hospitalier Public du Sud de l'Oise - site de Senlis
The Groupement Hospitalier Public du Sud de l'Oise in Senlis is actively engaged in advancing breast cancer care through precision oncology research. The center focuses on optimizing treatment strategies for elderly patients with hormone receptor-positive breast cancer, combining genomic profiling with clinical decision-making to personalize therapeutic approaches.
- Adjuvant chemotherapy strategies for elderly breast cancer patients
- Genomic grade assessment for relapse risk stratification
- HER2-negative, estrogen receptor-positive breast carcinoma treatment optimization
The center's research emphasizes improving overall survival outcomes in older women with breast cancer by integrating genomic grade classification into treatment selection. Their work addresses a critical gap in oncology by studying the comparative effectiveness of chemotherapy alone versus combination chemotherapy plus hormonotherapy in patients aged 70 and above with high-risk, ER-positive HER2-negative breast carcinoma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupement Hospitalier Public du Sud de l'Oise - site de Senlis
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Chemotherapy with Cyclophosphamide, Doxorubicin, and Docetaxel in ER-Positive HER2-Negative Breast Carcinoma in Women Over 70 | Unicancer | Phase III | Not Recruiting | Apr 2012 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 1 | Unknown | 2012-04-12 | 2012-04-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.